APTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 15:59):

Stats
Today's Volume	231 126
Average Volume	132 918
Market Cap	6.50M
EPS	$0 ( 2024-05-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0980
ATR14	$0.00400 (4.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-03	Khanna Ashish	Buy	375 000	Stock Option (Right to Buy)
2023-01-03	Riedel Norbert G	Buy	420 000	Stock Option (Right to Buy)
2023-01-03	Kidd Andrew	Buy	700 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 16 590 862 \| Sell: 1 518 818

Volume Correlation

Long: 0.42 (neutral)

Short: 0.45 (neutral)

Signal:(66.425) Neutral

Aptinyx Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptinyx Inc Correlation - Currency/Commodity

0.11
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.23
( neutral )

Aptinyx Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.950

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.950

FY	2021
Revenue:	$1.00M
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

FY	2020
Revenue:	$1.56M
Gross Profit:	$1 564.00 (0.10 %)
EPS:	$-1.020

Financial Reports:

No articles found.

Aptinyx Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.